Jiva.ai Secures £249.6k to Advance No-Code AI for Healthcare Diagnostics

Cardiff-based Jiva.ai Limited has raised £249.6k in a newly filed pre-seed round, bringing its estimated post-money valuation to £17.3m. The allotment was completed on 16 March 2026, with official filings confirmed today.

Founded in February 2019, Jiva.ai provides a no-code, multimodal artificial intelligence platform. The system enables non-technical users to build, validate, and deploy machine learning models using diverse data types, including medical imaging, text, and audio. While the platform serves enterprise markets such as finance and insurance, its primary focus remains the healthcare sector. The company specifically targets diagnostic applications, developing AI tools to assist in the early detection of prostate cancer and liver disease.

The healthcare industry generates vast amounts of fragmented data, from patient records to complex MRI scans. Historically, leveraging this data required dedicated teams of data scientists and software engineers. Jiva.ai solves this bottleneck by providing an interface that democratises access to advanced analytics. For example, their prostate cancer solution analyses MRI scans to highlight suspicious areas, which can reduce unnecessary biopsies and support earlier, more accurate clinical diagnoses. The company currently employs 17 people to support this mission.

The £249.6k injection is classified as a pre-seed round in recent filings, though it follows a £1.3m seed round previously secured in May 2021. That earlier round was backed by the Development Bank of Wales, Consilience Ventures, and the Wealth Club, a capital injection that prompted the company to establish its headquarters in Cardiff. The new £17.3m post-money valuation highlights a significant increase in the company's underlying equity value since its initial funding efforts.

This latest capital raise aligns with a massive surge in UK artificial intelligence investment, particularly within the health technology ecosystem. According to a March 2026 report published by NatWest and PitchBook, UK AI startups raised over £6bn in 2025. This figure accounted for more than a third of all UK venture capital, marking the highest share on record.

Furthermore, the UK government unveiled a £1.6bn AI research strategy in February 2026. This national framework places a heavy emphasis on accelerating healthcare breakthroughs, specifically highlighting early cancer detection and the reduction of clinical backlogs. Jiva.ai operates directly at this intersection of artificial intelligence and clinical diagnostics, positioning its no-code platform to capitalise on the growing demand for accessible, healthcare-focused machine learning tools.